rheumatoid arthritis drugs

Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
FDA clears second Remicade biosimilarIn what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).
Rheumatoid arthritis: Partnering for optimal care
Rheumatoid arthritis: Partnering for optimal careThe goal of this activity is to educate pharmacists and technicians in how best to assist patients in the use of medications used to treat rheumatoid arthritis.
PBM expands pay for value to RA drugsExpress Scripts will implement more programs that pay for drugs based on their effectiveness, according to the PBM’s chief medical officer Steve Miller, MD. Simultaneously, the PBM plans to implement a spending cap on diabetes medications.
First once-daily RA drug approvedFDA has approved tofacitinib citrate extended-release (Xeljanz XR, Pfizer) tablets for the treatment of moderate to severe rheumatoid arthritis (RA).
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
RA medications require unique cost considerationsWhen it comes to managing rheumatoid arthritis drugs, cost comes in various sizes and shapes.